TearLab Corporation Goes Private with Accelmed
Deal making hasn’t shut down entirely. The technology healthcare sectors are still attracting investors. The most recent is TearLab Corporation’s (OTCQB: TEAR) acquisition by Accelmed Partners, New York City-based group of funds investing in health tech companies in the medical device, diagnostics, and digital health areas. TearLab develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve the standard of care by testing for disease biomarkers in tears at the point of care. The TearLab Osmolarity Test, to aid in the diagnosis of Dry Eye Disease, is the first assay developed for the TearLab Osmolarity System. In connection with the acquisition,... Read More »
Takeda Divests Another Portfolio
In another step to slim down its product line, Takeda Pharmaceuticals (NYSE: TAK) announced another portfolio divestment. Orifarm Group A/S, an ambitious operator in the European pharmaceutical market, has purchased Takeda’s portfolio of select non-core over-the-counter and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland for $575 million. The portfolio includes a variety of OTC products and select prescription products in the respiratory, anti-inflammatory, cardiovascular and endocrinology therapeutic areas sold predominantly in Denmark, Norway, Belgium, Poland, Finland, Sweden, the Baltics and Austria. The portfolio... Read More »
Takeda Exits LatAm Portfolio
The Pharmaceutical sector, once a powerhouse of billion-dollar M&A activity, has been relatively quiet in recent years. One exception was Takeda Pharmaceutical’s (NYSE: TAK) takeover of Shire plc in 2018 for $81.5 billion. In March, the Japanese drug maker was back again, although on the sell-side. Takeda announced the sale of a portfolio of select non-core products exclusively in Latin America, including over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru. The buyer was Brazil’s largest pharmaceutical company, Hypera S.A., with a leading position in branded prescriptions, consumer health and... Read More »
Takeda Takes Aim at Shire
Big Pharma deals are making a comeback. Or so it seems from the speculation around Shire plc (NASDAQ: SHPG). Japanese drug maker Takeda Pharmaceutical Co. (OTCQB: TKPYY) has been buzzing around the UK-based Shire for nearly a month, making bid after bid. It seemed to begin on April 16, when Shire sold its oncology business to the French drug maker Servier, for $2.4 billion in cash. In 2017, the 0ncology business generated revenues of $262 million. The total consideration represents a revenue multiple of 9.2x 2017 revenues. The acquisition gives Servier a direct commercial presence in the United States and boosts its presence in cancer. Servier’s products will be commercialized in the... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
